M&G is an investment manager whose Catalyst strategy focuses on innovative private assets tackling environmental and social challenges.
Portfolio
7
companies
AUM
£342B
under management
Apollo Therapeutics
Apollo Therapeutics develops innovative medicines based on academic medical research breakthroughs.
Envisics
Envisics develops dynamic holographic technology for automotive augmented reality displays.
Level E Research
Level E Research develops bespoke artificial intelligence investment strategies for institutional clients.
Nuclera
Nuclera builds desktop bioprinters to accelerate protein expression and research workflows.
Osler Diagnostics
Osler Diagnostics develops portable tabletop blood-testing devices for clinical and decentralized settings.
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops DNA and RNA sequencing systems for scientific research and public health.
Jack Daniels
Chief Investment Officer
Jack brings investment management experience from roles at M&G Investments, alongside chair and advisory positions across the wealth and asset management sector.
David Montgomery
Managing Director at M&G Wealth
David brings senior operational and transformation experience from Aviva and M&G.
LinkedInZachary Webb
Head of EMEA Investments in Catalyst
The capital will support international expansion and recruitment as demand grows for the company grid stability technology.
"As we deliver more projects to support the global transition to Net Zero, this backing will empower us to deliver at scale, expand our commercial presence internationally, innovate further, and make a real contribution to a clean energy future."
The funding will support clinical development and drug discovery programmes derived from academic research.
"We are delighted to have completed the second close of our Series C financing in December and thank existing investors for their additional support, as well as welcoming new shareholders to the Company,"
The funding round was backed by M&G Investments and Van Tuyl Companies to accelerate product development and international expansion.
"To have such a strong close to our Series C strategic funding round is a testament to the momentum built by Dr. Christmas and the team at Envisics. We were an early investor in Envisics, and we welcome the very impressive roster of returning and new investors in this round."
M&G has taken a minority stake in the fintech to develop artificial intelligence investment solutions.
The round was backed by M&G Investments alongside existing supporters Oxford Science Enterprises, Braavos Investment Advisers, and Lansdowne Partners.
"The Osler Origin platform has the potential to transform healthcare by enabling anyone, anywhere, to access, understand, and act on their healthcare information. This new investment allows us to advance the Osler Origin towards market, and to realise our vision."
